AptarGroup (ATR) Stock Rallies As Q3 Results Highlight Margin Strain

AptarGroup walked into this Q3 2026 print with a premium P/E of 32.6x and a reputation as a steady compounder in packaging and drug delivery. The share price then jumped 5.0% on the first trading day after results, even as adjusted earnings per share for the quarter landed at the lower end of its recent range and net profit margin on a trailing basis sat at 6.7%, well below last year. That clash between a richer valuation and tighter profitability is the real story investors now need to weigh.

Appreciate AptarGroup's reputation as a steady compounder, but a 32.6x P/E appears high relative to its 6.7% trailing net margin. Compare that profile with our list of solid balance sheet and fundamentals stocks (25 results).

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs. Q3 2025): US$1,019.1m compared with US$961.1m (up about 6.0%)
• Net Income (Excl. Extra Items, Q3 2026 vs. Q3 2025): US$32.6m compared with US$127.9m (down about 74.5%)
• Basic EPS (Q3 2026 vs. Q3 2025): US$0.51 compared with US$1.95 (down about 73.6%)
• Adjusted EBITDA Margin (Q3 2026 vs. Q3 2025): 21.3% compared with about 23.2% (down about 190 basis points)

Earnings only tell part of AptarGroup's story, since cash flows often give you a clearer picture of what you are actually paying for in NYSE:ATR. Looking at AptarGroup's cash generation alone, the stock could be a striking 33% undervalued.

AptarGroup’s Pharma Ambition Meets Early Proof Points

AptarGroup’s bullish pitch hinges on pharma devices and services becoming a true earnings engine rather than just a storyline.

"Bullish analysts expect AptarGroup to turn its expanding nasal and systemic nose to brain drug delivery work into a higher margin pharma growth engine that deepens customer reliance on its devices and services."

Q3 shows real, if early, traction. Pharma core sales were flat on the surface, yet excluding emergency medicine destocking they rose 8%, with adjusted EBITDA margin at 36.4%. Intranasal devices now carry EU MDR CE marking; clinical nasal programs are running through Phase II and III; and the Pulmotree and Stevanato deals give customers clearer paths from trials to launch.

The price and this Narrative do not agree. → Uncover what this Narrative says AptarGroup is actually worth.

AptarGroup Bear Case: Margin Strain Still Visible

The harsher view centers on AptarGroup struggling to turn regulatory and sustainability pressure into a profitable packaging and pharma mix.

"Margin pressures stem from shifts in packaging trends, normalization of key pharma products, and rising legal and sustainability-related costs dampening earnings and cash flow."

Q3 results give this concern real footing. Adjusted EBITDA margin slipped 190 bps to 21.3%, with Beauty and Closures both showing thinner profitability despite solid core sales. Pharma margin eased 80 bps as emergency medicine destocking hit a richer line. Management also flagged multiquarter legal costs and higher sustainability capex, so the margin repair job is clearly incomplete this quarter.

Hunt For Mispriced Earnings Power

AptarGroup illustrates how a richer multiple can coexist with pressured profitability. The real opportunity is in stocks that could be undervalued before the market adjusts their earnings power.

• Company 1 - 38% below our estimate - turns a record high-horsepower engine backlog and data center power contracts into expanded capacity and focused capital spending.
• Company 2 - 37% below our estimate - tightens AI driven freight-matching and carrier vetting so heavy haul loads run with fewer disputes, delays and claims.
• Company 3 - 48% below our estimate - converts a record backlog of data center and modular projects into higher margin work with remote monitoring and disciplined execution.

That is three of the list. See every one of the 29 undervalued companies on it →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com